Yayınlar & Eserler

Yayın Ağı
Makaleler 11
Tümü (11)
SCI-E, SSCI, AHCI (8)
SCI-E, SSCI, AHCI, ESCI (11)
ESCI (2)
Scopus (10)
TRDizin (3)

1. Medication regimen complexity in cancer patients: an overlooked issue for healthcare team

Cifci S. A., Atik E., Dizdar O., Bayraktar-Ekincioglu A.
SUPPORTIVE CARE IN CANCER , cilt.33, sa.5, 2025 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

2. MANAGEMENT of ORAL CHEMOTHERAPY-RELATED PROBLEMS

Aras Atik E.
JOURNAL OF RESEARCH IN PHARMACY , cilt.27, ss.6-8, 2024 (Scopus) identifier identifier

3. International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions

Walker A., Chan A., Labra C. C., de Lemos M. L., Geirnaert M., Albert-Mari M. A., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.29, sa.5, ss.1065-1074, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

4. International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care

Holle L. M., Bilse T., Alabelewe R. M., Kintzel P. E., Kandemir E. A., Tan C. J., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.27, sa.4, ss.785-801, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

5. Does therapeutic drug monitoring of hydroxychloroquine improve treatment outcome in intensive care unit patients with COVID-19?

Tecen-Yucel K., Aras-Atik E., Bayraktar-Ekincioglu A.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , cilt.75, sa.4, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

6. Can Alpha-1 Antitrypsin Levels be Used to Predict the Prognosis of COVID-19 Therapy?

Aras Atik E., AYDURAN N., DEMİRKAN S. K.
TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES , cilt.17, sa.6, ss.576-577, 2020 (ESCI) Sürdürülebilir Kalkınma identifier identifier identifier

7. Are we aware of potential interactions between drugs used in lung cancer and drugs used in the treatment of COVID-19?

Aras-Atik E., Tecen-Yucel K., EKİNCİOĞLU A.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.7, ss.1807-1817, 2020 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

8. Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study

Aras E., EKİNCİOĞLU A., Kilickap S.
SUPPORTIVE CARE IN CANCER , cilt.28, sa.2, ss.691-699, 2020 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

9. Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports

Aras E., Tecen-Yucel K., EKİNCİOĞLU A., GÜLLÜ İ. H.
CLINICAL AND EXPERIMENTAL HEALTH SCIENCES , cilt.9, sa.2, ss.178-191, 2019 (ESCI) Sürdürülebilir Kalkınma identifier identifier

10. Drug related problems in patients on oncology wards

Aras E., Tecen K., Bayraktar-Ekincioglu A., Demirkan K.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY , cilt.40, sa.1, ss.247, 2018 (SCI-Expanded) identifier

11. Evaluation of G-CSF (granulocyte colony stimulating factor) use in oncology outpatient clinic by the PRS (patient risk score) assessment

Aras E., Tecen K., Bayraktar-Ekincioglu A., Demirkan K., Kilickap S.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY , cilt.40, sa.1, ss.247, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 1

1. Geriatri Polikliniğine Başvuran Hastalarda İlaç İlişkili Sorunların ve Uyuncun Değerlendirilmesi

Küçük H. D., Uğan R. A., Aras Atik E., Erat Şaşmaz M., Tosun Taşar P.
10. Ulusal Hastane ve Kurum Eczacıları Kongresi-TÜKED 2025, İskele, Kıbrıs (Kktc), 9 - 13 Nisan 2025, (Özet Bildiri)
Metrikler

Yayın

12

Yayın (WoS)

11

Yayın (Scopus)

10

Atıf (WoS)

38

H-İndeks (WoS)

3

Atıf (Scopus)

42

H-İndeks (Scopus)

3
BM Sürdürülebilir Kalkınma Amaçları